Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12651137 | 0.84 | CA2 (0.34) | CA2TSHRHSD17B10SLC6A4SLC6A3 | |
| SCHEMBL13995881 | 0.77 | ALDH1A1 (0.38) | TSHRHSD17B10SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL13995989 | 0.77 | ALDH1A1 (0.38) | TSHRHSD17B10SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL626634 | 0.75 | SLC6A4 (0.39) | TSHRHSD17B10SLC6A4SLC6A3NPC1 | |
| SCHEMBL70198 | 0.75 | — | — | |
| SCHEMBL172640 | 0.74 | CA2 (0.34) | CA2TSHRHSD17B10SLC6A4SLC6A3 | |
| SCHEMBL2530079 | 0.72 | CA2 (0.41) | CA2KMT2AALDH1A1 | |
| SCHEMBL8239568 | 0.70 | ALDH1A1 (0.38) | TSHRHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL15055229 | 0.70 | CA2 (0.40) | CA2ALDH1A1 | |
| SCHEMBL10411241 | 0.69 | KMT2A (0.61) | TSHRMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039493-B2 | Biaryl sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| CN-101808983-A | biaryl sulfonamide derivatives | HOFFMANN LA ROCHE | 2010-08-18 | — | — | CN | disclosed |
| EP-2205556-A2 | BIARYL SULFONAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009040289-A2 | BIARYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088459-A1 | NOVEL BIARYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088459-A1 | NOVEL BIARYL SULFONAMIDE DERIVATIVES | NR1H3, NR1H2, NR1H4 | CA2 2664/4885TSHR 279/4885HSD17B10 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.